Chen Shao Liang, Zhang Junjie, Yei Fei, Zhu Zhongsheng, Liu Zhizhong, Lin Song, Chu Jun, Yan Ji, Zhang Ruiyan, Kwan Tak W
Nanjing First Hospital of Nanjing Medical University, Department of Cardiology, 68# Changle Road, 210006, Nanjing, China.
Int J Cardiol. 2008 Jun 6;126(3):407-13. doi: 10.1016/j.ijcard.2007.05.004. Epub 2007 Jul 24.
The potential role of hydration in prevention of contrast-induced nephropathy (CIN) still remains to be unclear.
Nine-hundred and thirty-six patients scheduled for percutaneous coronary intervention (PCI) were enrolled into the present study, and divided into normal (serum creatinine<1.5 mg/dl) and abnormal (serum creatine> or =1.5 mg/dl) groups according to their baseline serum concentration of creatinine. Each group was further randomly divided into two subgroups: hydration and nonhydration. All patients in abnormal group took twice orally loading dose of 1200 mg acetylcysteine (ATLS) at 12 h before scheduled time for coronary angiogram and immediately after procedure. Creatinine concentration was remeasured at the time of admission (just before catheterization), every day for the following three days. The primary end point during 6-month follow-up included clinical driven revascularization (either PCI or CABG), death from all causes, and requiring emergency renal-replacement therapy.
The incidence of CIN was more commonly in abnormal group that in normal group (6.52% vs. 37.68%, p<0.001). Hydration had potentials in prevention of CIN only in patients with elevated baseline concentration of creatinine. Multivariate analysis demonstrated that the following variables remained to be significant factors correlating with CIN: age> or =70 years (odds ration [OR] 5.27, 95% confidence interval [CI] 1.94 to 13.07, p=0.0007), contrast volume> or =320 ml (OR 3.26, 95% CL 2.14 to 7.58, p=0.01), diabetes mellitus (OR 9.86, 95% CL 5.38 to 31.67, p<0.0001), and peripheral arterial disease (OR 11.25, 95% CL 5.12 to 43.19, p<0.0001). Patients with CIN in abnormal group had worse clinical outcomes, compared to patients with CIN in normal group.
Patients with CIN and preexisting renal insufficiency had worse clinical outcomes. Hydration with 0.45% sodium chloride alone had no potential effect on the occurrence of CIN in patients with normal renal function. Combination of hydration with ATLS could reduce the incidence of CIN in patients at high risk.
水化在预防对比剂肾病(CIN)中的潜在作用仍不明确。
936例计划接受经皮冠状动脉介入治疗(PCI)的患者纳入本研究,根据基线血清肌酐浓度分为正常组(血清肌酐<1.5mg/dl)和异常组(血清肌酐≥1.5mg/dl)。每组再随机分为两个亚组:水化组和非水化组。异常组所有患者在冠状动脉造影预定时间前12小时及术后立即口服两次负荷剂量1200mg乙酰半胱氨酸(ATLS)。在入院时(即将进行导管插入术前)以及随后三天每天重新测量肌酐浓度。6个月随访期间的主要终点包括临床驱动的血运重建(PCI或冠状动脉旁路移植术[CABG])、各种原因导致的死亡以及需要紧急肾脏替代治疗。
CIN的发生率在异常组比正常组更常见(6.52%对37.68%,p<0.001)。水化仅在基线肌酐浓度升高的患者中有预防CIN的潜力。多因素分析表明,以下变量仍是与CIN相关的显著因素:年龄≥70岁(比值比[OR]5.27,95%置信区间[CI]1.94至13.07,p = 0.0007)、对比剂用量≥320ml(OR 3.26,95%CI 2.14至7.58,p = 0.01)、糖尿病(OR 9.86,95%CI 5.38至31.67,p<0.0001)和外周动脉疾病(OR 11.25,95%CI 5.12至43.19,p<0.0001)。与正常组发生CIN的患者相比,异常组发生CIN的患者临床结局更差。
患有CIN和已有肾功能不全的患者临床结局更差。单纯用0.45%氯化钠水化对肾功能正常患者CIN的发生没有潜在影响。水化与ATLS联合可降低高危患者CIN的发生率。